Numis Securities reiterated their buy rating on shares of Vectura Group (LON:VEC) in a research report released on Friday, May 24th, ThisIsMoney.Co.Uk reports.
VEC has been the topic of several other research reports. Peel Hunt reaffirmed a hold rating on shares of Vectura Group in a report on Tuesday, April 2nd. Shore Capital reaffirmed a hold rating on shares of Vectura Group in a research report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. cut their target price on Vectura Group from GBX 110 ($1.44) to GBX 100 ($1.31) and set an overweight rating on the stock in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Buy and an average price target of GBX 122.86 ($1.61).
Shares of LON VEC traded up GBX 0.40 ($0.01) during midday trading on Friday, reaching GBX 81.40 ($1.06). 489,179 shares of the company traded hands, compared to its average volume of 4,610,000. Vectura Group has a 52 week low of GBX 65.85 ($0.86) and a 52 week high of GBX 90.15 ($1.18). The firm has a market capitalization of $540.99 million and a P/E ratio of -6.17. The stock’s 50-day moving average is GBX 77.82. The company has a current ratio of 2.35, a quick ratio of 1.90 and a debt-to-equity ratio of 0.81.
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Recommended Story: What is an SEC Filing?
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.